Loading clinical trials...
Loading clinical trials...
GnRH-a will be used to postpone period after vaginal repair for Cesarean Section Scar Defect(CSD) patients with adenomyosis which will be compared with CSD patients with adenomyosis who receive transvaginal surgery without GnRH-a, whether delayed period improving the CSD prognosis will be assessed.
Women with CSD complicated with adenomyosis will be enrolled in this study. They all will receive vaginal excision and suture of CSD and will be required to undergo examinations at 6-months after surgery. Interventioned group will be subcutaneous injected of Leuprorelin to postpone period after vaginal repair. It is be assumed that temporary menopause could improve inner conditions of uterus, there would be less local inflammation reaction which would be beneficial to the scar healed.
Age
18 - 50 years
Sex
FEMALE
Healthy Volunteers
No
Shanghai Jiaotong University xinhua hospital
Shanghai, Shanghai Municipality, China
Start Date
May 1, 2023
Primary Completion Date
April 30, 2025
Completion Date
April 30, 2026
Last Updated
April 23, 2024
94
ESTIMATED participants
Leuprorelin
DRUG
Lead Sponsor
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT05590104